[go: up one dir, main page]

AR104518A1 - Una vacuna contra la infección por trypanosoma cruzi - Google Patents

Una vacuna contra la infección por trypanosoma cruzi

Info

Publication number
AR104518A1
AR104518A1 ARP160101264A ARP160101264A AR104518A1 AR 104518 A1 AR104518 A1 AR 104518A1 AR P160101264 A ARP160101264 A AR P160101264A AR P160101264 A ARP160101264 A AR P160101264A AR 104518 A1 AR104518 A1 AR 104518A1
Authority
AR
Argentina
Prior art keywords
trypanosoma cruzi
vaccine against
against infection
infection
sialidase
Prior art date
Application number
ARP160101264A
Other languages
English (en)
Original Assignee
Baeremaecker Barros Carlos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baeremaecker Barros Carlos filed Critical Baeremaecker Barros Carlos
Priority to ARP160101264A priority Critical patent/AR104518A1/es
Priority to PCT/CL2017/050020 priority patent/WO2017190260A1/es
Priority to US16/311,597 priority patent/US20190351035A1/en
Priority to UY0001037226A priority patent/UY37226A/es
Publication of AR104518A1 publication Critical patent/AR104518A1/es
Priority to CONC2018/0012531A priority patent/CO2018012531A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una composición de vacuna contra la infección por Trypanosoma cruzi que comprende, al menos, una proteína mutante trans-sialidasa de Trypanosoma cruzi (SEQ 1) y, como adyuvante, una mezcla de un aceite mineral altamente purificado y monooleato de manida.
ARP160101264A 2016-05-04 2016-05-04 Una vacuna contra la infección por trypanosoma cruzi AR104518A1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ARP160101264A AR104518A1 (es) 2016-05-04 2016-05-04 Una vacuna contra la infección por trypanosoma cruzi
PCT/CL2017/050020 WO2017190260A1 (es) 2016-05-04 2017-05-02 Una vacuna contra la infección por trypanosoma cruzi
US16/311,597 US20190351035A1 (en) 2016-05-04 2017-05-02 Vaccine against trypanosoma cruzi infection
UY0001037226A UY37226A (es) 2016-05-04 2017-05-04 Una vacuna contra la infección por trypanosoma cruzi
CONC2018/0012531A CO2018012531A2 (es) 2016-05-04 2018-11-22 Una vacuna contra la infección por trypanosoma cruzi

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP160101264A AR104518A1 (es) 2016-05-04 2016-05-04 Una vacuna contra la infección por trypanosoma cruzi

Publications (1)

Publication Number Publication Date
AR104518A1 true AR104518A1 (es) 2017-07-26

Family

ID=59485534

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101264A AR104518A1 (es) 2016-05-04 2016-05-04 Una vacuna contra la infección por trypanosoma cruzi

Country Status (5)

Country Link
US (1) US20190351035A1 (es)
AR (1) AR104518A1 (es)
CO (1) CO2018012531A2 (es)
UY (1) UY37226A (es)
WO (1) WO2017190260A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020144464A1 (en) * 2019-01-07 2020-07-16 Genome Research Limited Novel trypanosomal vaccine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008011632A (es) * 2006-03-17 2008-10-17 Vib Vzw Vacuna novedosa contra infeccion de trypanosoma cruzi.

Also Published As

Publication number Publication date
WO2017190260A1 (es) 2017-11-09
UY37226A (es) 2017-11-30
US20190351035A1 (en) 2019-11-21
CO2018012531A2 (es) 2018-12-14

Similar Documents

Publication Publication Date Title
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
CO2017009663A2 (es) Una cepa mutante de paenibacillus, compuestos antifúngicos, y un método para identificar dicha cepa de paenibacillus
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
UY35011A (es) Método para aumentar la resistencia al estrés abiótico de una planta
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
BR112017003891A2 (pt) métodos e composições para induzir imunidade protetora contra infecção por filovírus
MX2018016037A (es) Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa.
MX390729B (es) Composiciones y usos de bacillus
UA115348C2 (uk) Композиція для попередження інфекції mycoplasma spp.
CL2018001279A1 (es) Spodoptera frugiperda resistente a vip3a.
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
WO2019086646A8 (en) Feline leukemia virus vaccine
MX2017014414A (es) Metodo para la produccion de circovirus porcino y vacunas pcv2.
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
PH12020500042A1 (en) Method for preparing influenza working virus seed stock, method for preparing influenza vaccine using same seed stock, and virus seed stock prepared by same method
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
EA201792593A1 (ru) Пестивирусные вакцины против врожденного тремора
MX2018012671A (es) Combinacion, usos terapeuticos y usos profilacticos.
BR112017005645A2 (pt) método de preparar cinamaldeído
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
CO2018012531A2 (es) Una vacuna contra la infección por trypanosoma cruzi
MX2020001570A (es) Uso terapeutico o no terapeutico de protozoos del genero willaertia como fungistatico y/o fungicida.
PH12019501306B1 (en) Adjuvants

Legal Events

Date Code Title Description
FB Suspension of granting procedure